Advancing CAR-T and NK Cell Therapy Product Development
With proven efficacy for cancer treatments, immuno-oncology has become one of the most prolific fields in cancer prevention and therapeutics, bringing promise to cancer researchers and patients around the world.
Date: Wednesday, August 25
Time: 10:00 am EST (7:00 am PST)
Multiple CAR-T cell therapy products have been approved by the FDA for patient treatments, while many Investigational New Drug (IND) for NK cells are still underway.
In this webinar, we will present:
1. Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC)
2. Development of a non-invasive image-based cytometry method for NK cell cytolysis in 2D and 3D models
3. Improving quality and throughput of cell counting method following ISO Cell Counting Standards for cell and gene therapy